Roche Holding AG, Biogen Idec, Inc. (Massachusetts) Suspends Arthritis Treatment Ocrelizumab After Deaths

March 8, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Reuters -- Swiss drugmaker Roche Holding AG (ROG.VX) and U.S.-listed Biogen Idec (BIIB.O) are suspending rheumatoid arthritis and lupus treatment ocrelizumab after it caused deaths, casting doubt over the drug's future.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase 3

Biogen